Jefferies downgraded Allakos to Hold from Buy with a price target of $1.50, down from $6. The company’s lirentelimab missed on the primary endpoint in chronic spontaneous urticaria and atopic dermatitis and it is restructuring, the analyst tells investors in a research note. The firm is moving to the sidelines with Allakos shifting its focus to AK006.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ALLK:
